GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A
Semaglutide is generally discussed as a GLP-1 receptor agonist model, Tirzepatide as a dual GIP and GLP-1 receptor agonist model, and Retatrutide as a triple receptor agonist model involving GLP-1, GIP, and glucagon receptor pathways
Even when not breastfeeding, people who take GLP-1s are more likely to become nutrient deficient
These doses provide meaningful metabolic benefits including improved insulin sensitivity and enhanced fat oxidation without the profound appetite suppression that makes eating adequate calories difficult
10 When coadministered with a TZD, exenatide was associated with an 11% increased risk of hypoglycemia, compared with 7% for placebo
The GLP-1 and GIP receptors in the digestive system slow gastric emptying